These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33241993)

  • 21. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Multiple Sclerosis in Portugal: A Multicentre Study.
    Correia AS; Augusto L; Meireles J; Pinto J; Sousa AP
    Acta Med Port; 2016 Aug; 29(7-8):425-431. PubMed ID: 27914152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The management of pediatric multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    J Child Neurol; 2012 Nov; 27(11):1384-93. PubMed ID: 22914373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis.
    Ghassemi R; Brown R; Banwell B; Narayanan S; Arnold DL;
    Mult Scler; 2015 May; 21(6):718-25. PubMed ID: 25480858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in multiple sclerosis at general hospital level.
    Hellgren J; Risedal A; Källén K
    Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalamus volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients.
    Rojas JI; Murphy G; Sanchez F; Patrucco L; Fernandez MC; Miguez J; Funes J; Golimstok A; Cristiano E
    Neuroradiol J; 2018 Aug; 31(4):350-355. PubMed ID: 29869576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression of regional grey matter atrophy in multiple sclerosis.
    Eshaghi A; Marinescu RV; Young AL; Firth NC; Prados F; Jorge Cardoso M; Tur C; De Angelis F; Cawley N; Brownlee WJ; De Stefano N; Laura Stromillo M; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Geurts JJG; Vrenken H; Wottschel V; Leurs CE; Uitdehaag B; Pirpamer L; Enzinger C; Ourselin S; Gandini Wheeler-Kingshott CA; Chard D; Thompson AJ; Barkhof F; Alexander DC; Ciccarelli O
    Brain; 2018 Jun; 141(6):1665-1677. PubMed ID: 29741648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging.
    Righart R; Biberacher V; Jonkman LE; Klaver R; Schmidt P; Buck D; Berthele A; Kirschke JS; Zimmer C; Hemmer B; Geurts JJG; Mühlau M
    Ann Neurol; 2017 Oct; 82(4):519-529. PubMed ID: 28833433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal.
    Palavra F; Figueiroa S; Correia AS; Tapadinhas F; Cerqueira J; Guerreiro RP; de Sá J; Sá MJ; Almeida S; Mota P; Sousa L
    Mult Scler Relat Disord; 2021 Jun; 51():102865. PubMed ID: 33714125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
    Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
    Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis.
    Alroughani R; Ahmed SF; Al-Hashel J
    Pediatr Neurol; 2015 Dec; 53(6):508-12. PubMed ID: 26383244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.